Background Fumaric acid esters (FAEs) are used to treat psoriasis and are known to cause lymphopenia in roughly
Introduction
Fumaric acid esters (FAEs) have been used in systemic psoriasis treatment since 1959. 1 Some retrospective observational studies have shown that FAEs are safe and beneficial for long-term clinical use. [2] [3] [4] [5] According to the European 6 and the recently updated German 7 evidence-and consensus-based guidelines, FAEs are recommended for the induction and long-term treatment of adult patients with moderate-to-severe psoriasis. The reference product Fumaderm â , which is a defined mixture of dimethyl fumarate (DMF) and three salts of monoethyl fumarate, 8 received marketing approval in Germany in 1994. 9 As a new DMF-only drug with a European registration for moderate-tosevere psoriasis, Skilarence â became available in 2017. 10, 11 Psoriasis is a multi-factorial autoimmune disease that involves the activation of many pathways driven by numerous cells. 12, 13 Among these, T lymphocytes (CD3 + ) control and orchestrate inflammation. Peripheral blood CD3 + T cells are thought to be activated and subsequently recruited from circulation during the development of psoriatic lesions. 14 Thus, in psoriatic plaques, T helper lymphocytes (CD4 + ) are found predominantly in the upper dermis, and T cytotoxic lymphocytes (CD8 + ) are predominantly observed in the epidermis. DMF and its metabolite monomethyl fumarate (MMF), which is rapidly formed by DMF hydrolysis, are currently thought to be the pharmacologically active FAEs that are used to treat psoriasis. [15] [16] [17] Numerous experimental studies, which have mostly concentrated on the effects of DMF in vitro, have described pleiotropic immunomodulating properties that particularly propagate development of an inflammatory T h 1/T h 17 immune response towards an antiinflammatory T h 2 immune response in psoriasis patients. [17] [18] [19] [20] Under treatment with FAEs, leukopenia development that is mainly attributed to lymphopenia is commonly observed [2] [3] [4] [5] [21] [22] [23] and is of significant clinical importance. 15, 16 Our group 24, 25 and others 23, 26, 27 showed that the number of peripheral blood lymphocyte subsets is considerably reduced and inflammatory CD3 + T cells disappear from psoriatic lesions, 28 thus limiting the harmful effect mediated by these cells in the skin. However, the in vivo mechanism remains to be elucidated. 15, 16 Recently, several cases of progressive multifocal leukoencephalopathy (PML) in lymphopenic FAE-treated patients have raised concerns about drug safety. 29, 30 This rare, but life-threatening opportunistic infection, which is caused by reactivation of the John Cunningham virus, seems to be related particularly to FAEinduced CD4 + and CD8 + T-cell lymphopenia. Therefore, in compliance with the newly adapted drug safety requirements of the European Medicines Agency (EMA), 31 the manufacturer of Fumaderm â32 currently recommends monitoring of the blood count every 4 weeks and immediate discontinuation of the treatment if the absolute lymphocyte count (ALC) drops below 500/ lL. If the ALC drops below 700/lL, the dose should be halved; if the ALC remains below this value during a follow-up check after 4 weeks, then treatment should be discontinued. However, regular monitoring of the lymphocyte subset count is not essential. 7, 32 The present substudy of our recently published single-centre retrospective observational study 2 27 and will provide a better understanding of FAE-based therapy management.
Methods

Study design
This investigator-initiated subcohort study is based on continuously recorded clinical and laboratory findings on psoriasis patients followed at the Department of Dermatology, Venereology and Allergology of the Ruhr University Bochum in Germany who were prescribed Fumaderm â between January 1996 and October 2012. The single-centre retrospective observational study's goals and methods have been previously described in detail. 2 
Study population
There were 371 psoriasis patients enrolled into the substudy, and we quantitatively analysed peripheral blood lymphocyte subsets data using flow cytometry before and during FAE treatment. Briefly, FAEs were initiated using a gradually increasing dosing regimen. 8 All patients typically attended our outpatient department monthly for clinical assessment and quarterly for complete blood count tests. As a non-routine part of our follow-up examinations, flow cytometric analyses were performed at baseline (371 patients) and, whenever possible, 3 AE 1 months (172 patients), 6 AE 1 months (148 patients), 12 AE 1 months (218 patients), 24 AE 1 months (203 patients) and 36 AE 1 months (119 patients) after initiating FAE treatment and at irregular intervals thereafter (77 patients).
Flow cytometry
Peripheral blood leucocyte counts were routinely determined using an automated particle counter. Flow cytometric methods were used to identify and determine the peripheral blood lymphocyte subset percentages and absolute counts. The following antibodies (BD Biosciences, San Jose, CA, USA), directed against mature human lymphocyte subsets, were used: T lymphocytes (CD3 . The antibodies were conjugated to the following fluorescent dyes: fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein cyanine 5.5 (PerCP-Cy5.5), phycoerythrin-cyanine 7 (PE-Cy7), allophycocyanin (APC) and allophycocyanin-cyanine 7 (APC-Cy7 Table 5 .
Flow cytometry was introduced in our laboratory in December 1995. 24 At that time, we used a FACScan TM flow cytometer equipped with a single blue laser. For standard immunophenotyping, six different tubes with different antibody combinations were required. Later, we worked with a FACSCalibur TM flow cytometer equipped with two lasers (red and blue). Standard immunophenotyping was performed with antibody combinations in two separate tubes. Generally, the basic immunophenotyping quality has not changed much over the last decades, but today the results of multicolour experiments are faster and provide higher grades of information density. Over the 17-year study period, flow cytometry was used in our laboratory in close compliance with the guidelines of the Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards). [34] [35] [36] All laboratory personnel who performed immunophenotyping were blinded to the patients' clinical status. 42 and at least a two-point reduction in baseline sPGA score; and (ii) the proportion of patients with PASI 75 (considered a less stringent reasonable therapeutic goal) 43 compared with baseline. We estimated the proportion of psoriasis patients who reached these defined 'events' of effectiveness in their respective varying observation periods using the Kaplan-Meier method. 44 The corresponding event dates were defined as the date of first occurrence during treatment. Censorship occurred at the last available follow-up date at which the effectiveness event had failed to occur. All Kaplan-Meier failure curves of event by group are depicted with the number of patients 'at risk'. 45, 46 'Patients at risk' were defined as patients receiving treatment at a certain time point who had not yet reached the effectiveness event. We summarized the Kaplan-Meier failure curve results by presenting the median event with a 95% CI. 47 This is the time point at which the cumulative response rate exceeds 50%. We used log-rank tests to descriptively compare the event between groups, taking the whole observation period into account. 48 Because of the retrospective study design, no imputation of missing values was performed. Data were analysed using SAS â statistical analysis software, version 9.4 (SAS Institute, Cary, NC, USA).
Data sources and handling
Ethical approval
The Ethics Committee of the Medical Faculty of the Ruhr University Bochum approved the study protocol of the singlecentre retrospective observational study (registration no. 4203-12; 6 February 2012).
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Results
Patient and treatment characteristics
Baseline demographic characteristics and comorbidities of the subset of 371 psoriasis patients are shown in Table 1 . The mean patient age was 47.8 years (range, 9-90 years), and 235 (63.3%) of the patients were male. In the subgroups with decreased CD4 + and/or CD8 + T-cell counts below 200 and 140/lL, respectively, patients were more likely to be older when initiating FAE therapy. Table 2 shows baseline disease and treatment characteristics of the total subcohort. In the subgroups with decreased CD4 + and/or CD8 + T-cell counts below 200 and 140/lL, respectively, patients spent a longer time under continuous FAE therapy. However, many values for body mass index, smoking status and PASI were missing. A non-significantly greater proportion of patients prematurely discontinued FAE therapy in the 'CD4 + T cells <200/lL and CD8 + T cells <140/lL' subgroup compared with other groups (Table 3) . Premature discontinuation occurred most often as a result of the T-lymphocyte alterations. However, the proportions of patients who discontinued FAE therapy because of clinical remission and lack of efficacy were lowest and highest, respectively, in the 'CD4 + T cells ≥200/lL and CD8 + T cells ≥140/lL' subgroup. Table 4 provides the frequencies of abnormal leucocyte and lymphocyte subset counts of different thresholds during FAE therapy. In the subcohort, 60.9% of the psoriasis patients developed lymphopenia. Severe lymphopenia (CTCAE grade 3 or 4) occurred in 14.3% of the patients. Changes in leucocyte and lymphocyte subset counts measured within a 3-year period to monitor the safety of the FAE therapy are displayed in Table 5 . The mean lymphocyte count decreased significantly by 23.9% within the first 3 months of treatment. Over the course of treatment, mean lymphocyte counts further decreased significantly by about 40% of baseline values. The reduction in the mean leucocyte count was comparable but less pronounced, with a total reduction reaching 20% over the course of therapy. Among subsets, the mean CD4 + T-cell count declined significantly by 49.9%, which was similar to the nadir after 2 years of therapy, whereas the mean CD8 + T-cell count declined significantly by 55.7%. Over the course of therapy, the reduction in the mean CD8 + T-cell count was generally more pronounced compared with the reduction in the mean CD4 + T-cell count, which was also reflected by a significantly increased mean CD4/CD8 ratio, with a maximum mean percentage change of 49.5% from the baseline. Reaching the lowest mean values after 1 year of therapy, CD19 + B-cell and CD56 + NK cell counts were significantly *P-value derived from chi-square test; **P-value derived from Kruskal-Wallis test; bold, P ≤ 0.05. BMI, body mass index; FAE, fumaric acid ester; n, number of patients with available data; SD, standard deviation. Comorbidity includes any of the following: hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, chronic liver disease, degenerative joint disease, alcohol/drug abuse, mental illness, coronary heart disease, other pulmonary disease, other chronic gastrointestinal disease, malignant neoplasm, chronic kidney disease, heart failure, chronic obstructive pulmonary disease, peptic ulcer disease, cerebrovascular disease, chronic viral infection, osteoporosis and other disease.
reduced by 27.7% and 21.9%, respectively, compared with mean baseline values. Table 6 shows the results from the Cox regression analyses. Based on univariate analysis, the statistically significant factors possibly associated with T-cell lymphopenia, as defined, were older age (P < 0.0001; age group 40-55 years, P = 0.012; age group >55 years, P < 0.0001) and a lower absolute leucocyte (P = 0.05) or lymphocyte (P = 0.002) count when initiating FAE therapy. Based on the multivariate analysis, the age factor remained statistically significant for the development of T-cell lymphopenia (P < 0.0001). The therapy regimen 'FAEs + MTX' showed an inverse effect on the development of T-cell lymphopenia (P = 0.03). A similar statistically non-significant trend could already be observed in the univariate analysis (P = 0.07). The robustness of these results was confirmed using a sensitivity analysis (data not shown).
Determinants for FAE-induced T-cell lymphopenia
Impact of T-cell lymphopenia on FAE effectiveness
Although not statistically significant, sPGA and PASI assessments showed a tendency towards a faster improvement in the severity of psoriatic skin lesions in the two groups with decreased CD4 + and/or CD8 + T-cell counts below 200 and 140/ lL, respectively (Figs 1,2) . In both groups, the time from FAE therapy initiation to a cumulative sPGA response rate of 50% for achieving 'light' status and at least a 2-point reduction in baseline PGA was 0.49 years (95% CI: 0.49-0.99 years) compared with 0.99 years (95% CI: 0.49-0.99 years) in the group with CD4
+ and CD8 + T-cell counts greater than or equal to 200 and 140/lL (Fig. 1) . The sPGA results were not significantly different among the three groups (P = 0.07).
In the group with decreased CD4 + and CD8 + T-cell counts below 200 and 140/lL, the time from FAE therapy initiation to a cumulative PASI 75 response rate of 50% was 3 years (95% CI: 2-4 years) compared with 3.8 years (95% CI: 3-6.3 years) in the group with CD4 + and CD8 + T-cell counts greater than or equal to 200 and 140/lL and 3.9 years (95% CI: 3-6.7 years) in the group with CD4 + or CD8 + T-cell counts below 200 and 140/lL (Fig. 2) . The PASI 75 results were not significantly different among the three groups (P = 0.43).
Discussion
This retrospective investigation of the largest-ever subcohort from our single-centre observational study 2 27 The risk of T-cell lymphopenia increased significantly with the psoriasis patient's age at the time of initiation of FAE therapy, a correlation that has thus far only been described in multiple sclerosis (MS) patients receiving DMF therapy with Tecfidera â . 49, 50 Unexpectedly, the risk of T-cell lymphopenia decreased significantly for the combination therapy with MTX and folic acid supplementation. An increased infection rate was not detected in our subcohort. Figure 1 Cumulative percentage of sPGA responders (event: sPGA = 'light' and at least a 2-point reduction in baseline sPGA score) after initiation of FAE treatment by groups stratified for absolute CD4
26,51
+ and CD8 + T-cell counts under FAE therapy: 1, 'CD4 + T cells ≥200/lL and CD8 + T cells ≥140/lL'; 2, 'CD4 + T cells <200/lL or CD8 + T cells <140/lL'; and 3, 'CD4 + T cells < 200/lL and CD8 + T cells <140/lL'. Kaplan-Meier failure curves with the number of patients 'at risk' (on therapy) in each group. Log-rank test: P = 0.07. FAE, fumaric acid ester; sPGA, static Physician's Global Assessment.
Cumulative response rate
Years after initiation of FAE treatment Figure 2 Cumulative percentage of PASI 75 responders after initiation of FAE treatment by groups stratified for absolute CD4 + and CD8 + T-cell counts under FAE therapy: 1, 'CD4 + T cells ≥200/lL and CD8 + T cells ≥140/lL'; 2, 'CD4 + T cells <200/lL or CD8 + T cells <140/lL'; and 3, 'CD4 + T cells <200/lL and CD8 + T cells <140/lL'. Kaplan-Meier failure curves with the number of patients 'at risk' (on therapy) in each group. Log-rank test: P = 0.43. FAE, fumaric acid ester; PASI, Psoriasis Area and Severity Index.
No deaths occurred. Conversely, our data strongly suggest that T-cell lymphopenia is a condition necessary for an enhanced FAE therapy effectiveness, 24 ,26,52,53 a finding that was first reported by Nieboer et al. 23 in a smaller psoriasis patient cohort.
Biological effects of FAEs on peripheral blood lymphocytes
Leukopenia and lymphopenia occur frequently during FAE treatment, 7, 54 but, in our experience, are usually reversible after FAE dose reduction, and in severe and persistent cases, treatment discontinuation is required to decrease the risk of infection. 55, 56 Severe lymphopenia has been reported in about 3% of FAE-treated psoriasis patients, while in up to 63% of patients, the lymphocyte reductions were mild. 3, 57 The changes in the absolute leucocyte and lymphocyte subset counts observed in the present substudy are consistent with those recently reported in smaller cohorts by Sondermann et al. 26 However, the exact mechanism by which MMF, as the main systemically active metabolite, produces the effects seen in the immune system, particularly lymphopenia, has not yet been fully elucidated. It may be possible that MMF directly induces apoptosis in peripheral blood T cells, although CD4 + or CD8 + T-cell culture experiments showed that MMF does not increase the frequency of apoptotic cells. 62, 75 Instead, in vitro DMF leads to the inhibition of T-cell cytokine secretion, T-cell proliferation and, in higher concentrations, the induction of apoptosis in a subpopulation of activated, but not resting, human T cells by impairing the nuclear factor-kappa B signalling pathway in particular. 19, 60, 62, [75] [76] [77] [78] Our results also showed that the reason for the age-related increased susceptibility for FAE-induced lymphopenia is not well understood, 49 but it may be related to 'immunosenescence'. 29, 30 An additional lymphopenia predictor is a lower ALC when FAE therapy is initiated, which was described by Longbrake et al.
49
While MTX induces apoptosis of in vitro activated T cells, 82 it only slightly increased the risk of leukopenia in randomized controlled trials (RCTs). 83 Dividing cytokine production into thus, the CD4/CD8 ratio increased. Folic acid supplementation was shown to rapidly restore the rate of T-cell proliferation and lower the CD4/CD8 ratio. 85 These results may advance our understanding on how the MTX-related folic acid supplementation might elicit a protective effect against lymphopenia. Thus, an RCT is warranted to substantiate our findings. Gold et al. 86 recently reported that the percentage of DMF-treated MS patients with low vitamin B9 (folic acid) and vitamin B12 baseline levels was slightly higher in those experiencing gastrointestinal-related events. The authors hypothesized that patients with higher serum vitamin B levels may experience fewer gastrointestinal symptoms. 
FAE-induced lymphopenia linked to responder status
Limitations
The present subcohort study has some potential limitations. First, our data are limited in its retrospective nature, leading to missing values. Second, data reported here reflect the clinical experience of a single tertiary care centre and may not be representative of the entire psoriasis patient population. However, our real-life results can be extrapolated to psoriasis patients who have been exposed to FAEs for several years. Third, this study was limited by the risk of selection bias due to non-routine performance of flow cytometric analyses and the lack of a parallel control group, both of which complicate the interpretation of the causality between FAE treatment and T-cell lymphopenia. Fourth, despite the continuous strict compliance to high-quality standards in our laboratory throughout the entire study period [34] [35] [36] and the continuous use of the same laboratory team (S.H. and colleague) for the performance of flow cytometry analyses, we cannot strictly rule out an influence of the techniques developed in flow cytometry in the interim on lymphocyte phenotyping. Finally, examination of the lymphocyte subset count recovery over time after FAE discontinuation would have also been desirable, but these data were not interpretable because patients who discontinued FAE use as a result of lymphopenia typically began other disease-modifying therapies immediately thereafter. 63 
Conclusions
Fumaric acid ester-induced (T cell) lymphopenia does not seem to cause a significantly attenuated immunosurveillance 2,4,5 as long as ALCs are closely monitored in accordance with the guidelines. 7, 32 The occurrence of severe or opportunistic infections such as PML during treatment with FAEs was mostly linked to exposure to prolonged uncontrolled lymphopenia. 57 However, severe or opportunistic infections can also occur in patients with unremarkable total lymphocyte counts; 27, 66, 87, 90, 91 thus, monitoring the ALC, which is not a good indicator of CD4 + and CD8 + T-cell counts, seems to be a crude way to measure the cellular immune response. 29, 30, 39 However, the CD8 + Tcell count may be a better surrogate marker for risk of infection than the ALC. 66, 68 The current Summary of Product Characteristics for Fumaderm â requires a monthly complete blood count and lymphocyte count. In the current German guidelines, 7 26 and 140/lL for a CD8 + T-cell count. This increased vigilance in T-cell monitoring appears to be particularly warranted in older patients, 49 especially those who are older than 40 years of age. 29, 30 However, further prospective investigation is required to establish evidence-based recommendations and thus overcome the discrepancies in leucocyte and lymphocyte count monitoring between licensed FAE-containing drugs 11, 32, 92 that are currently available. 93 
